{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,27]],"date-time":"2025-12-27T15:11:26Z","timestamp":1766848286653,"version":"build-2065373602"},"reference-count":15,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2020,4,1]],"date-time":"2020-04-01T00:00:00Z","timestamp":1585699200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,4,1]],"date-time":"2020-04-01T00:00:00Z","timestamp":1585699200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100005565","name":"Janssen Biotech","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005565","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007054","name":"Meso Scale Diagnostics","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005564","name":"Gilead Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005564","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010877","name":"ViiV Healthcare","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010877","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","dldjournalonline.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Digestive and Liver Disease"],"published-print":{"date-parts":[[2020,4]]},"DOI":"10.1016\/j.dld.2019.12.007","type":"journal-article","created":{"date-parts":[[2020,1,17]],"date-time":"2020-01-17T07:53:43Z","timestamp":1579247623000},"page":"447-451","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Safety and efficacy of daclatasvir at doses other than 60\u202fmg daily in HIV\/HCV co-infected subjects: Data from the ICONA\/HepaICONA foundation cohorts"],"prefix":"10.1016","volume":"52","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4965-8789","authenticated-orcid":false,"given":"Roberto","family":"Rossotti","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alessandro","family":"Tavelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefano","family":"Bonora","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonella","family":"Cingolani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sergio","family":"Lo Caputo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Annalisa","family":"Saracino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alessandro","family":"Soria","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Letizia","family":"Marinaro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Caterina","family":"Uberti-Foppa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cristina","family":"Mussini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Massimo","family":"Puoti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonella","family":"d'Arminio Monforte","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.dld.2019.12.007_bib0005","doi-asserted-by":"crossref","first-page":"3991","DOI":"10.1073\/pnas.1203110110","article-title":"Modeling shows that the NS5A inhibitor daclatasvir has two modes of action and yields a shorter estimate of the hepatitis C virus half-life","volume":"110","author":"Guedj","year":"2013","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.dld.2019.12.007_bib0010","unstructured":"American Association for the Study of Liver Disease. HCV guidance: recommendations for testing, managing, and treating hepatitis C. Available at https:\/\/www.hcvguidelines.org. (Accessed 27 February 2019)."},{"year":"2018","series-title":"EASL recommendations: treatment of hepatitis C","author":"European Association for the Study of the Liver","key":"10.1016\/j.dld.2019.12.007_bib0015"},{"key":"10.1016\/j.dld.2019.12.007_bib0020","unstructured":"World Health Organization. Guidelines for the care and treatment of persons diagnosed with chronic hepatitis C virus infection. Available at https:\/\/www.who.int\/hepatitis\/publications\/hepatitis-c-guidelines-2018\/en\/. (Accessed 12 May 2019)."},{"year":"2017","series-title":"Daklinza\u2122 (daclatasvir) tablets, for oral use: US prescribing information","author":"Bristol-Myers Squibb Company","key":"10.1016\/j.dld.2019.12.007_bib0025"},{"key":"10.1016\/j.dld.2019.12.007_bib0030","article-title":"Access and response to direct acting agents (DAA) in HIV-HCV co-infected patients in Italy: data from the Icona cohort","volume":"12","author":"D\u2019Arminio Monforte","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/j.dld.2019.12.007_bib0035","unstructured":"Division of AIDS (DAIDS) Table for Grading the Severity of Adverse Events. Available at https:\/\/rsc.tech-res.com\/docs\/default-source\/safety\/daids_ae_grading_table_v2-_nov-2014.pdf. (Accessed 02 February 2019)."},{"key":"10.1016\/j.dld.2019.12.007_bib0040","unstructured":"O\u2019Mara E., Randall D., Passarell J., et al. Population pharmacodynamic assessment of atazanavir exposure, uridine diphosphate-glucuronosyl transferase (UGT) 1A1 genotype and safety in healthy subjects. Paper presented at: 42nd Interscience Congress on Antimicrobial Agents and Chemotherapy; September 27-30 San Diego, CA. 2002."},{"key":"10.1016\/j.dld.2019.12.007_bib0045","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1056\/NEJMoa1503153","article-title":"Daclatasvir plus sofosbuvir for HCV in patients coinfected with HIV-1","volume":"373","author":"Wyles","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.dld.2019.12.007_bib0050","doi-asserted-by":"crossref","first-page":"931","DOI":"10.3851\/IMP2674","article-title":"Assessment of pharmacokinetic interactions of the HCV NS5A replication complex inhibitor daclatasvir with antiretroviral agents: ritonavir-boosted atazanavir, efavirenz and tenofovir","volume":"18","author":"Bifano","year":"2013","journal-title":"Antivir Ther (Lond)"},{"key":"10.1016\/j.dld.2019.12.007_bib0055","doi-asserted-by":"crossref","first-page":"1867","DOI":"10.1007\/s12325-016-0407-5","article-title":"Daclatasvir: overview of drug-drug interactions with antiretroviral agents and other common concomitant drugs","volume":"33","author":"Garimella","year":"2016","journal-title":"Adv Ther"},{"key":"10.1016\/j.dld.2019.12.007_bib0060","unstructured":"Landis C.S., Nelson D.R., Sulkowski M.S., et al. An integrated safety analysis of daclatasvir + sofosbuvir, with or without ribavirin, in patients with chronic HCV infection. Paper presented at: 66th Annual Meeting of the American Association for the Study of Liver Diseases; November 15-17; Boston, MA. 2015."},{"key":"10.1016\/j.dld.2019.12.007_bib0065","first-page":"328","article-title":"Mechanisms of accelerated liver fibrosis progression during HIV infection","volume":"4","author":"Debes","year":"2016","journal-title":"J Clin Transl Hepatol"},{"key":"10.1016\/j.dld.2019.12.007_bib0070","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1097\/01.mcg.0000210105.66994.dc","article-title":"Progression to cirrhosis in Latinos with chronic hepatitis C: differences in Puerto Ricans with and without human immunodeficiency virus coinfection and along gender","volume":"40","author":"Rodr\u00edguez-Torres","year":"2006","journal-title":"J Clin Gastroenterol"},{"key":"10.1016\/j.dld.2019.12.007_bib0075","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1086\/499055","article-title":"Do type and duration of antiretroviral therapy attenuate liver fibrosis in HIV-hepatitis C virus-coinfected patients?","volume":"42","author":"Verma","year":"2006","journal-title":"Clin Infect Dis"}],"container-title":["Digestive and Liver Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1590865819309545?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1590865819309545?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T04:11:11Z","timestamp":1761624671000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1590865819309545"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4]]},"references-count":15,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2020,4]]}},"alternative-id":["S1590865819309545"],"URL":"https:\/\/doi.org\/10.1016\/j.dld.2019.12.007","relation":{},"ISSN":["1590-8658"],"issn-type":[{"type":"print","value":"1590-8658"}],"subject":[],"published":{"date-parts":[[2020,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Safety and efficacy of daclatasvir at doses other than 60\u202fmg daily in HIV\/HCV co-infected subjects: Data from the ICONA\/HepaICONA foundation cohorts","name":"articletitle","label":"Article Title"},{"value":"Digestive and Liver Disease","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.dld.2019.12.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Editrice Gastroenterologica Italiana S.r.l. Published by Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}